Alnylam’s Phase 3 Clinical Trials with Givosiran [transcript][audio]
Key Takeaways
- Key Insight: Segment Overview: Jeff Miller, General Manager of the Givosiran program at Alnylam discusses the ENVISION Alnylam Phase 3 trial of its investigational RNAi therapeutic givorsiran for the treatment …
- Clinical Perspective: Guest: Jeff Miller Presenter: Neal Howard Guest Bio: Mr.
- Why It Matters: This discussion provides healthcare professionals with actionable insights relevant to clinical practice and patient care.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
Segment Overview: Jeff Miller, General Manager of the Givosiran program at Alnylam discusses the ENVISION Alnylam Phase 3 trial of its investigational RNAi therapeutic givorsiran for the treatment of acute hepatic porphyrias.
Guest: Jeff Miller
Presenter: Neal Howard
Guest Bio: Mr. Miller joined Alnylam in May 2016 as general manager, with 20 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Alnylam, he held a variety of general management and commercial leadership roles in the United States, Europe, and Canada. While with Alexion, Merck Serono, Boehringer Ingelheim, and Eli Lilly, he worked across many disease areas in Primary Care, Specialty Care, Oncology, and Rare Diseases. Jeff earned his Bachelor of Arts in Communications from the State University of New York at Oswego and his MBA from Boston University
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
